StreetInsider.com News Articles

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading.

Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/838122249?pwd=X5tkHKiy

A live webcast and replay of the conference call will also be available through the

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

A live webcast and replay of the conference call will also be available through the

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

A live webcast and replay of the conference call will also be available through the

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

A live webcast and replay of the conference call will also be available through the

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

A live webcast and replay of the conference call will also be available through the

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

A live webcast and replay of the conference call will also be available through the

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

A live webcast and replay of the conference call will also be available through the

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Thu, 23 Jul 2026 08:30:00 -0400

A live webcast and replay of the conference call will also be available through the

Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on 'Solid Partnership Momentum'

Tue, 21 Jul 2026 09:23:20 -0400

Benchmark analyst Robert Wasserman reiterated a Buy rating and $90.00 price target on Halozyme Therapeutics (NASDAQ: HALO).

The analyst commented, "Halozyme announced this morning a licensing agreement with Incyte Pharmaceuticals (INCY, Not Rated) using HALO's Enhanze drug development technology to develop subcutaneous formulations of Incyte's INCA033989, a monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). The financial terms of the agreement were not disclosed, except to relate that HALO will receive an upfront payment from Incyte as well as potential development milestones and commercial royalties. Incyte currently has two clinical programs ongoing with INCA033989 in MPNs, one in pivotal trials

Halozyme and Incyte sign drug delivery licensing agreement

Mon, 20 Jul 2026 08:00:40 -0400

Halozyme Therapeutics (NASDAQ: HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ: INCY) to develop subcutaneous formulations of INCA033989, a mutant calreticulin (mutCALR)-targeted monoclonal antibody being studied in patients with mutCALR-expressing myeloproliferative neoplasms.

The agreement grants Incyte rights to use Halozyme's ENHANZE drug delivery technology with its mutCALR development program. Incyte also holds an option to nominate up to two additional targets for use with the technology.

Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the

Halozyme and Incyte sign drug delivery licensing agreement

Mon, 20 Jul 2026 08:00:40 -0400

Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the

Halozyme and Incyte sign drug delivery licensing agreement

Mon, 20 Jul 2026 08:00:40 -0400

Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the

Halozyme and Incyte sign drug delivery licensing agreement

Mon, 20 Jul 2026 08:00:40 -0400

Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the

Halozyme and Incyte sign drug delivery licensing agreement

Mon, 20 Jul 2026 08:00:40 -0400

Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the

Halozyme and Incyte sign drug delivery licensing agreement

Mon, 20 Jul 2026 08:00:40 -0400

Under the terms of the deal, Halozyme will receive an upfront payment from Incyte, along with potential milestone payments and royalties on net sales of any commercialized medicines that use the

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology